A CDMO Perspective On Commercial Technology Transfer Of Oral Solid Dosage Products

Commercial manufacturing-site transfers require more than simple administrative changes; they demand an integrated strategy that bridges donor-site knowledge with receiving-site capabilities. Successfully transitioning oral solid dosage products involves harmonizing multi-layered regulatory expectations—such as ICH guidelines and regional validation frameworks—into practical, product-specific execution plans. Bridging potential equipment differences and analytical gaps early prevents costly delays and ensures consistent commercial performance. Furthermore, adopting a life-cycle validation model maintains a state of control from initial process design through routine manufacturing. Robust cross-functional governance and rigorous material risk assessments are essential to safeguard product quality and regulatory compliance across global markets.
Access the full white paper to explore the complete stage-gated transfer framework and gain expert guidance on achieving a seamless, dependable commercial supply.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.